# Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

> **NCT00658411** · NA · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** deferoxamine

## Key facts

- **NCT ID:** NCT00658411
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Closed due to slow patient accrual
- **Last updated:** 2013-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658411, "Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00658411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*